Moleculin Biotech, Inc. (NASDAQ: MBRX) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Moleculin Announces Online Publication of Preclinical Data Demonstrating Significant Activity of Annamycin in Venetoclax Resistant AML Model [Yahoo! Finance]
Moleculin Announces Online Publication of Preclinical Data Demonstrating Significant Activity of Annamycin in Venetoclax Resistant AML Model
Moleculin Biotech, Inc. (NASDAQ: MBRX) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Moleculin Biotech, Inc. (NASDAQ: MBRX) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.